Neurobiological Tech (NTII) | Stock Discussion Forums

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical
Neurobiological Tech (NTII)

An SI Board Since September 1996

Posts	SubjectMarks	Bans	Symbol
1494	40	0	NTII

Emcee: Miles Rhyne Hoffman, CFA	Type: Unmoderated

Introduction Market Data Compact

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Posted
1294	Namenda Statistics .... Week ending April 9th - Total Prescriptions: ---------	John McCarthy	-	4/29/2004
1293	Neurobiological Technologies Initiates Pivotal Phase III Clinical Trial Program	nigel bates	-	4/20/2004
1292	Namenda(TM), our recently introduced NMDA receptor antagonist for the treatment	John McCarthy	-	4/20/2004
1291	BW Online - SEVERE EDIT There's reason to believe Forest can deliver. Nam	John McCarthy	-	3/30/2004
1290	Paul is probably raising the money so that he can pay all the attorneys' fee	JMarcus	-	3/2/2004
1289	Neurobiological Technologies Raises $19.4 Million in Private Equity Financing T	mopgcw	-	3/2/2004
1288	Neurobiological Technologies Upgraded to Strong Buy Rating by Dutton & Assoc	John McCarthy	-	2/26/2004
1287	capturing just under 21% CSFB raises its target on Forest Labs to $84 from $78	John McCarthy	-	2/24/2004
1286	Hi - Please tell your wife that all things considered ... memantine cannot but	John McCarthy	-	2/24/2004
1285	My wife just called me from a small city in East Texas. Her only living blood re	Arthur Radley	-	2/23/2004
1284	NI never off topic ... don't give anecdotal a second thought ... and to my	John McCarthy	-	2/12/2004
1283	John: Here's what I had written in the Dec issue on Grant Krafft's work	NeuroInvestment	-	2/12/2004
1282	NI ran across this this morning and thought it interesting and that you might f	John McCarthy	-	2/12/2004
1281	Neurobiological Technologies Reports Fiscal 2004 Second Quarter Results Monday	mopgcw	-	2/9/2004
1280	Introduction While the mild to moderate Alzheimer’s disease (AD) market *****	John McCarthy	-	2/4/2004
1279	2004 IMS America prescription data Below is a post by Ricardouno from the FRX	John McCarthy	-	2/4/2004
1278	Marc - thanks again. Additionally - I have posted both of your posts to the Ya	John McCarthy	-	1/22/2004
1277	Here are some more nuggets from today’s presentation. · Paul said that FRX	JMarcus	-	1/22/2004
1276	Marc - thank you for summarizing the meeting and for talking to the important bu	John McCarthy	-	1/22/2004
1275	Thanks for sharing (eom).	mopgcw	-	1/22/2004
1274	At his JM Dutton presentation today Paul said that such a rapid grab of market s	JMarcus	-	1/22/2004
1273	Namenda = 9.2% market share .... Marketing efforts for Forest Laboratories'	John McCarthy	-	1/20/2004
1272	IMS data .... from a post on the FRX board .... Out of the Gate Data by: Ricar	John McCarthy	-	1/13/2004
1271	NeuroInvestment .... In simple words - I can't thank you enough - for both	John McCarthy	-	1/7/2004
1270	BACE=beta-secretase. Here is a section on secretase inhibition from the NI Decem	NeuroInvestment	-	1/7/2004

Go to reply# or date (mm/dd/yy):